{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T05:47:31Z","timestamp":1672984051748},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2015.104","type":"journal-article","created":{"date-parts":[[2015,12,13]],"date-time":"2015-12-13T02:12:13Z","timestamp":1449972733000},"page":"e376-e376","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses"],"prefix":"10.1038","volume":"5","author":[{"given":"M","family":"Wetzler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F E","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Akard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H J","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"BFbcj2015104_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","volume":"13","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 2013; 13: 584\u2013591.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj2015104_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/cncr.29240","volume":"121","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-up. Cancer 2015; 121: 1637\u20131644.","journal-title":"Cancer"},{"key":"BFbcj2015104_CR3","unstructured":"Synribo (omacetaxine mepesuccinate) for injection [prescribing information]. Teva Pharmaceuticals USA, Inc: North Wales, PA, 2014."},{"key":"BFbcj2015104_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2009.012781","volume":"95","author":"D Milojkovic","year":"2010","unstructured":"Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010; 95: 224\u2013231.","journal-title":"Haematologica"},{"key":"BFbcj2015104_CR5","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011; 117: 1822\u20131827.","journal-title":"Blood"},{"key":"BFbcj2015104_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/leu.2011.55","volume":"25","author":"EK Allan","year":"2011","unstructured":"Allan EK, Holyoake TL, Craig AR, Jorgensen HG . Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells. Leukemia 2011; 25: 985\u2013994.","journal-title":"Leukemia"},{"key":"BFbcj2015104_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/leu.2012.305","volume":"27","author":"E Jabbour","year":"2013","unstructured":"Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance\/intolerance. Leukemia 2013; 27: 907\u2013913.","journal-title":"Leukemia"},{"key":"BFbcj2015104_CR8","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1182\/blood.V120.21.3747.3747","volume":"120","author":"MJ Mauro","year":"2012","unstructured":"Mauro MJ, Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R et al. Multivariate analyses of the clinical and molecular parameters associated with efficacy and safety in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ponatinib in the PACE trial. Blood 2012; 120: 3747 abstract.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj2015104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj2015104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj2015104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T10:04:03Z","timestamp":1672913043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj2015104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":8,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["BFbcj2015104"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.104","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,11]]},"assertion":[{"value":"11 December 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Meir Wetzler reported personal fees from Teva, Ariad and Boehringer Ingelheim, and grants from Bristol\u2013Myers Squibb during the conduct of the study. Hagop M Kantarjian reports research grants from Teva during the conduct of the study. Michele Baccarani reports personal fees from Ariad, Bristol\u2013Myers Squibb, Pfizer and Novartis during the conduct of the study. Franck E Nicolini reports grants, personal fees and non-financial support from Novartis Pharma, personal fees from Bristol\u2013Myers Squibb and personal fees from Ariad during the conduct of the study. Luke Akard reports grants and personal fees from Teva, Ariad and Novartis, personal fees from Bristol\u2013Myers Squibb and grants from Pfizer outside the conduct of the study. Elizabeth Li is employed by PharmaStat LLC, and reports payment for statistical analysis from Teva during the conduct of the study. Mihaela Munteanu reports employment by Teva during the conduct of the study. Jorge Cortes reports grants from Teva during the conduct of the study, and grants and personal fees from Ariad, Bristol\u2013Myers Squibb, Novartis and Pfizer outside the submitted work. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}